EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions

Atsushi Kawai, Taro Shimizu, Hiroki Tanaka, Shintaro Shichinohe, Jessica Anindita, Mika Hirose, Eigo Kawahara, Kota Senpuku, Makoto Shimooka, Le Thi Quynh Mai, Ryo Suzuki, Takuto Nogimori und 6 weitere

Molecular Therapy · 2025-02 · 33 (2) · 529-547

DOI: 10.1016/j.ymthe.2024.12.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-02. Verfasst von Atsushi Kawai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka …. Hauptthemen laut MEDLINE: Influenza A Virus, H5N1 Subtype, Influenza Vaccines, Nanoparticles, RNA, Messenger. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BIKEN Foundation, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA vaccines based on lipid nanoparticles (mRNA-LNPs) are promising vaccine modalities. However, mRNA-LNP vaccines frequently cause adverse reactions such as swelling and fever in humans, partly due to the inflammatory nature of LNP. Modification of the ionizable lipids used in LNPs is one approach to avoid these adverse reactions. Here, we report the development of mRNA-LNP vaccines with better protective immunity and reduced adverse reactions using LNPs, which contain a disulfide (SS)-cleavable bond and pH-activated lipid-like materials with oleic acid (ssPalmO) as an ionizable lipid (LNPssPalmO). We used mRNA expressing H5N1 subtype high-pathogenicity avian influenza virus-derived hemagglutinin or neuraminidase to generate mRNA-LNP vaccines against H5N1 influenza. Compared with conventional LNPs, mRNA-LNPssPalmO induced comparable antigen-specific antibodies and better interferon-γ (IFN-γ)-producing T helper type 1 responses in mice. Both mRNA-LNPssPalmO and conventional mRNA-LNPs conferred strong protection against homologous H5N1 virus challenge. In addition, mRNA-LNPssPalmO showed better cross-protection against heterologous H5N1 virus challenge compared with conventional mRNA-LNPs. Furthermore, we observed that mRNA-LNPssPalmO induced less-inflammatory responses (e.g., inflammatory cytokine production, vascular hyperpermeability) and fewer adverse reactions (e.g., weight loss, fever) compared with conventional mRNA-LNPs. These results suggest that mRNA-LNPssPalmO would be a safe alternative to conventional vaccines to overcome mRNA-LNP vaccine hesitancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H5N1 SubtypeInfluenza VaccinesNanoparticlesRNA, MessengermRNA VaccinesLipidsOrthomyxoviridae InfectionsAnimalsMiceAntibodies, ViralHumansFemaleInterferon-gammaInfluenza, HumanLiposomesMice, Inbred BALB C

Stichwörter der Autor:innen

adverse reactioncross-protectionhigh-pathogenicity avian influenza virusionizable lipidlipid nanoparticlemRNA vaccine

Substanzen

Influenza VaccinesRNA, MessengermRNA VaccinesLipid NanoparticlesAntibodies, ViralLipidsInterferon-gammaLiposomes

Autor:innen und Institutionen

  • Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Rese…
  • Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Vaccine Creation Group, BIKEN In…
  • Center for Advanced Modalities and DDS, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Ao…
  • Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi 980-8578, Japan.
  • Laboratory for Cryo-EM Structural Biology, Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Förderung

  • BIKEN Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kawai, A., Shimizu, T., Tanaka, H., Shichinohe, S., Anindita, J., Hirose, M., Kawahara, E., Senpuku, K., Shimooka, M., Quynh Mai, L. T., Suzuki, R., Nogimori, T., Yamamoto, T., Hirai, T., Kato, T., Watanabe, T., Akita, H., & Yoshioka, Y. (2025). Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Molecular Therapy, 33(2), 529-547. https://doi.org/10.1016/j.ymthe.2024.12.032

Vancouver

Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, et al. Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Molecular Therapy. 2025;33(2):529-547. doi:10.1016/j.ymthe.2024.12.032

BibTeX
@article{Kawai2025,
  author = {Kawai, Atsushi and Shimizu, Taro and Tanaka, Hiroki and Shichinohe, Shintaro and Anindita, Jessica and Hirose, Mika and Kawahara, Eigo and Senpuku, Kota and Shimooka, Makoto and Quynh Mai, Le Thi and Suzuki, Ryo and Nogimori, Takuto and Yamamoto, Takuya and Hirai, Toshiro and Kato, Takayuki and Watanabe, Tokiko and Akita, Hidetaka and Yoshioka, Yasuo},
  title = {Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {2},
  pages = {529--547},
  doi = {10.1016/j.ymthe.2024.12.032}
}
Kostenlos starten →